Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Summary
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.FDA Commissioner to provide National Priority Vouchers to appropriate psychedelic drugs with Breakthrough Therapy designation.
- 2.FDA and DEA to establish a pathway for eligible patients to access psychedelic drugs under the Right to Try Act, including Schedule I handling authorizations.
- 3.HHS to allocate at least $50 million to support state governments advancing psychedelic drug programs.
- 4.HHS, FDA, and VA to collaborate with the private sector to increase clinical trial participation and data sharing for psychedelic drugs.
- 5.Attorney General to initiate and complete timely review for rescheduling of Schedule I substances that successfully complete Phase 3 clinical trials for serious mental health disorders.
Market Implications
This action is expected to significantly accelerate the development, approval, and patient access to psychedelic-based therapies for mental health, creating a more favorable regulatory and funding environment for companies in this nascent industry.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Veterans Health Administration Novel Therapeutics Preparedness Act
Presidential Memorandum: Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Domestic Petroleum Production, Refining, and Logistics Capacity
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.